-
-
Hepatitis B virus (HBV) reactivation after rituximab or other immune suppressive therapies may lead to serious adverse outcomes. The authors retrospectively reviewed HBV serology of CD20 positive B-cell lymphoma without active HBV (i.e., negative HBsAg) before and after rituximab. Of the 230 tested, 56 (24%) were anti-HBc positive; the five cases of HBV reactivation all occurred in these 56 patients. Moreover, four of the five were anti-HBs negative (a.k.a, isolated anti-HBc). All received entacavir with the only HBV complication of transaminitis. None of the anti-HBc negative patients reactivated. Isolated anti-HBc, particularly lacking anti-HBs, may be at heightened risk of HBV reactivation after rituximab.
-
-
A 31-year-old g1p0 caucasian woman in the seventh month of pregnancy is referred for management of her T2N0Mx "triple-negative" breast cancer.
-
There are several forms of amyloidosis, each with distinct patterns of protein deposition and resulting clinical presentations.
-
-
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
A nationwide survey conducted in March 2008 of 429 pediatricians and 419 family physicians in the United States with response rates of 81% and 79%, respectively, showed that 98% of pediatricians and 80% of family physicians were administering HPV vaccine in their offices.
-
Two-hundred eleven adipose biopsies were obtained from 59 patients participating in the Western Australia HIV cohort study.
-
Investigators in lausanne, switzerland cultured the noses of 405 new hospital workers for Staphylococcus aureus, then checked them again about nine months later.
